Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2003;108:2524-2529
Published online before print October 27, 2003, doi: 10.1161/01.CIR.0000096482.02567.8C
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
108/20/2524    most recent
01.CIR.0000096482.02567.8Cv1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Takahashi, M.
Right arrow Articles by Sobue, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Takahashi, M.
Right arrow Articles by Sobue, K.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*OMIM
*UniGene
*Substance via MeSH
Related Collections
Right arrow Smooth muscle proliferation and differentiation
Right arrow Mechanism of atherosclerosis/growth factors

(Circulation. 2003;108:2524.)
© 2003 American Heart Association, Inc.


Basic Science Reports

Epiregulin as a Major Autocrine/Paracrine Factor Released From ERK- and p38MAPK-Activated Vascular Smooth Muscle Cells

Masanori Takahashi, MD*; Ken’ichiro Hayashi, PhD*; Kenji Yoshida, MD*; Yasuyuki Ohkawa, PhD; Toshi Komurasaki, PhD; Akira Kitabatake, MD, PhD; Akira Ogawa, MD, PhD; Wataru Nishida, MD, PhD; Masahiko Yano, MD, PhD; Morito Monden, MD, PhD; Kenji Sobue, MD, PhD

From the Department of Neuroscience (K.H., Y.O., W.N., K.S.) and the Department of Surgery and Clinical Oncology (M.Y., M.M.), Osaka University Graduate School of Medicine, Osaka, Japan; the Department of Cardiovascular Medicine, Hokkaido University, Graduate School of Medicine (M.T., A.K.), Sapporo, Japan; the Department of Neurosurgery, Iwate Medical University School of Medicine (K.Y., A.O.), Morioka, Japan; and the Molecular Biology Laboratory, Medical Research Laboratories, Taisho Pharmaceutical Co, Ltd (T.K.), Saitama, Japan.

Correspondence to Dr Kenji Sobue, Department of Neuroscience, Osaka University Graduate School of Medicine (D13), 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan. E-mail sobue{at}nbiochem.med.osaka-u.ac.jp

Received December 31, 2002; de novo received April 23, 2003; revision received July 18, 2003; accepted July 21, 2003.

Background— The coordinated activation of extracellular signal–regulated kinase (ERK) and p38 mitogen-activated protein kinase (p38MAPK) is critical for the induction of vascular and visceral smooth muscle cell (SMC) dedifferentiation. We previously reported that on the forced activation of both MAPKs, visceral SMCs secrete a non–heparin-binding protein factor(s) that is involved in the dedifferentiation of neighboring SMCs. In this study, we sought to identify the dedifferentiation factor(s) derived from vascular SMCs (VSMCs).

Methods and Results— We fractionated the VSMC dedifferentiation factor(s) in the conditioned medium obtained from differentiated VSMCs in which both ERK and p38MAPK were forcedly activated and identified epiregulin as a major autocrine/paracrine factor for VSMC dedifferentiation. The epiregulin-induced VSMC dedifferentiation was mediated through the coordinated activation of ERK and p38MAPK. Unsaturated lysophosphatidic acid and platelet-derived growth factor-BB, which are potent VSMC dedifferentiation factors, rapidly upregulated epiregulin mRNA expression in an ERK- and p38MAPK-dependent manner. Reverse transcriptase–polymerase chain reaction and/or immunohistological analyses revealed the restricted expression of epiregulin in human atherosclerotic and balloon-injured rat arteries, in which the phenotypic modulation of medial VSMCs occurred in vivo.

Conclusions— Epiregulin is released from VSMCs primed by atherogenic factors and acts as a major autocrine/paracrine factor for VSMC dedifferentiation. It may be involved in the progression of vascular remodeling such as atherosclerosis.


Key Words: vasculature • remodeling • muscle, smooth • atherosclerosis




This article has been cited by other articles:


Home page
Cardiovasc ResHome page
G. E. White, T. C.C. Tan, A. E. John, C. Whatling, W. L. McPheat, and D. R. Greaves
Fractalkine has anti-apoptotic and proliferative effects on human vascular smooth muscle cells via epidermal growth factor receptor signalling
Cardiovasc Res, November 12, 2009; (2009) cvp341v2.
[Abstract] [Full Text] [PDF]


Home page
Toxicol PatholHome page
N. Wakamatsu, J. B. Collins, J. S. Parker, M. Tessema, N. P. Clayton, T.-V. T. Ton, H.-H. L. Hong, S. Belinsky, T. R. Devereux, R. C. Sills, et al.
Gene Expression Studies Demonstrate that the K-ras/Erk MAP Kinase Signal Transduction Pathway and Other Novel Pathways Contribute to the Pathogenesis of Cumene-induced Lung Tumors
Toxicol Pathol, July 1, 2008; 36(5): 743 - 752.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
E. J. Cornish, B. J. Hurtgen, K. McInnerney, N. L. Burritt, R. M. Taylor, J. N. Jarvis, S. Y. Wang, and J. B. Burritt
Reduced Nicotinamide Adenine Dinucleotide Phosphate Oxidase-Independent Resistance to Aspergillus fumigatus in Alveolar Macrophages
J. Immunol., May 15, 2008; 180(10): 6854 - 6867.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
S. Li, F. Takeuchi, J.-a. Wang, Q. Fan, T. Komurasaki, E. M. Billings, G. Pacheco-Rodriguez, J. Moss, and T. N. Darling
Mesenchymal-epithelial interactions involving epiregulin in tuberous sclerosis complex hamartomas
PNAS, March 4, 2008; 105(9): 3539 - 3544.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
I. Airoldi, E. Di Carlo, C. Cocco, G. Taverniti, T. D'Antuono, E. Ognio, M. Watanabe, D. Ribatti, and V. Pistoia
From the Cover: Endogenous IL-12 triggers an antiangiogenic program in melanoma cells
PNAS, March 6, 2007; 104(10): 3996 - 4001.
[Abstract] [Full Text] [PDF]


Home page
Toxicol SciHome page
R. D. Patel, D. J. Kim, J. M. Peters, and G. H. Perdew
The Aryl Hydrocarbon Receptor Directly Regulates Expression of the Potent Mitogen Epiregulin
Toxicol. Sci., January 1, 2006; 89(1): 75 - 82.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. Zhuang, Y. Yan, J. Han, and R. G. Schnellmann
p38 Kinase-mediated Transactivation of the Epidermal Growth Factor Receptor Is Required for Dedifferentiation of Renal Epithelial Cells after Oxidant Injury
J. Biol. Chem., June 3, 2005; 280(22): 21036 - 21042.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
K. Hayashi, K. Shibata, T. Morita, K. Iwasaki, M. Watanabe, and K. Sobue
Insulin Receptor Substrate-1/SHP-2 Interaction, a Phenotype-dependent Switching Machinery of Insulin-like Growth Factor-I Signaling in Vascular Smooth Muscle Cells
J. Biol. Chem., September 24, 2004; 279(39): 40807 - 40818.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
S. Shirasawa, S. Sugiyama, I. Baba, J. Inokuchi, S. Sekine, K. Ogino, Y. Kawamura, T. Dohi, M. Fujimoto, and T. Sasazuki
Dermatitis due to epiregulin deficiency and a critical role of epiregulin in immune-related responses of keratinocyte and macrophage
PNAS, September 21, 2004; 101(38): 13921 - 13926.
[Abstract] [Full Text] [PDF]